Vandetanib (ZD6474) induces antiangiogenesis through mTOR–HIF-1 alpha–VEGF signaling axis in breast cancer cells

OBJECTIVE: Vandetanib, also known as ZD6474, has recently been proved to be a clinical drug for cancer by targeting vascular endothelial growth factor receptor 2 (VEGFR2), EGFR, and RET tyrosine kinases. We hypothesized that vandetanib will be a drug candidate for breast cancer treatment by targetin...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ling, Yu, Jingkui, Jiao, Shuhong, Wang, Wei, Zhang, Fen, Sun, Shiqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278704/
https://www.ncbi.nlm.nih.gov/pubmed/30555244
http://dx.doi.org/10.2147/OTT.S175578

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278704/
https://www.ncbi.nlm.nih.gov/pubmed/30555244
http://dx.doi.org/10.2147/OTT.S175578

Ejemplares similares